Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.42 |
| ▸ | NOS3 | P29474 | 4/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9687757 | 0.76 | NOS2 (0.47) | NOS2NOS3NOS1 | |
| SCHEMBL4986132 | 0.75 | NOS2 (0.42) | NOS2NOS3TLR8NOS1 | |
| SCHEMBL9686545 | 0.73 | MAPT (0.49) | NOS2NOS3TLR8NOS1 | |
| SCHEMBL9687039 | 0.71 | NOS2 (0.44) | NOS2NOS3NOS1 | |
| SCHEMBL9536189 | 0.70 | NOS2 (0.47) | NOS2NOS3NOS1 | |
| SCHEMBL9687045 | 0.70 | NOS2 (0.39) | NOS2NOS3TLR8NOS1 | |
| SCHEMBL8123469 | 0.69 | MPO (0.49) | NOS2NOS3NOS1 | |
| SCHEMBL3264472 | 0.68 | NOS2 (0.52) | NOS2NOS3TLR8NOS1 | |
| SCHEMBL25256924 | 0.68 | NOS2 (0.41) | NOS2NOS3NOS1 | |
| SCHEMBL9686463 | 0.68 | NOS3 (0.37) | NOS2NOS3TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390811-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-24 | — | — | US | disclosed |
| US-7361657-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-22 | — | — | US | disclosed |
| US-7173054-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-7173034-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-20070021410-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20060154913-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V (BE) (BE) | 2006-07-13 | — | — | US | disclosed |
| US-20050239771-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. | 2005-10-27 | — | — | US | disclosed |
| US-20050234047-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. | 2005-10-20 | — | — | US | disclosed |
| US-6924287-B1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACATICA, N.V. (BE) | 2005-08-02 | — | — | US | disclosed |
| EP-1196408-B1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2004-09-15 | — | — | EP | disclosed |
| EP-1418175-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-12 | — | — | EP | disclosed |
| EP-1196408-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001000611-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-04 | — | — | WO | disclosed |
| EP-0539421-B1 | NOVEL OXAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1998-09-23 | — | — | EP | disclosed |
| WO-1992001687-A1 | NOVEL OXAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154913-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | NOS2 3448/4885NOS3 2246/4885TLR8 1680/4885 |
| US-20050234047-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | NOS2 3441/4885NOS3 2235/4885TLR8 1711/4885 |
| US-20070021410-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | NOS2 3448/4885NOS3 2246/4885TLR8 1680/4885 |
| US-20050239771-A1 | Respiratory syncytial virus replication inhibitors | CCNB3, CCNA1, CDK2 | NOS2 3104/4885NOS3 1941/4885TLR8 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.